March 2, 2013 Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium
March 1, 2013 The advantages of frontotemporal degeneration drug development (Part 2 of frontotemporal degeneration: the next therapeutic frontier)
March 1, 2013 Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium
February 21, 2013 Critical Path Institute Names Martha Brumfield CEO The Board of Directors of the Critical Path Institute (C-Path) announced today that Martha Brumfield, Ph.D., has been named interi
January 30, 2013 CFAST Announces Parkinson’s Disease Drug Development Milestone: Release and Availability of a PD Therapeutic Area Data Standard
January 12, 2013 Patient-Reported Outcomes In Clinical Trials Of CKD-Related Therapies: Report Of A Symposium Sponsored By The National Kidney Foundation And The US Food And Drug Administration
January 8, 2013 Understanding Placebo Responses In Alzheimer’s Disease Clinical Trials From The Literature Meta-data And CAMD Database
January 6, 2013 ePRO Systems Validation: Clearly Defining The Roles Of Clinical Trial Teams And ePRO System Providers